| AVB |
Report |
Q2 2026 Core FFO/share |
BEAT |
pred ~$2.85 vs. cons $2.80 |
MEDIUM |
| AVB |
Report |
Q2 2026 Same-Store Residential Revenue Growth (YoY) |
BEAT |
pred ~1.9% vs. cons 1.7% |
MEDIUM |
| AVB |
Report |
Q2 2026 Same-Store NOI Growth (YoY) |
MISS |
pred ~0.3% vs. cons 0.6% |
LOW |
| AVB |
Guide |
FY2026 Core FFO/share guidance |
LOWER |
guide ~$11.25 (reaffirmed midpoint) vs. cons $11.30 (FY2026) |
MEDIUM |
| AVB |
Guide |
FY2026 Same-Store Revenue Growth guidance |
LOWER |
guide ~1.4% midpoint (0.4%-2.4% range, reaffirmed) vs. cons 1.6% (FY2026) |
LOW |
| AVB |
Guide |
EQR merger annual synergy commentary (no Q2 conf call held) |
UNCHANGED |
guide ~$175M gross synergies reiterated vs. cons/prior $175M (post-close run-rate) |
MEDIUM |
| AVB |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.3% |
— |
LOW |
| AVB |
Return |
5-day cumulative residual |
+0.2% (STABILIZE) |
AVB skipped its Q2 conference call entirely given the pending EQR merger, so there is minimal incremental forward commentary or Q&A to drive analyst revision swings either way. With guidance likely reaffirmed rather than raised (mirroring the Q1 pattern despite a beat) and full-year Core FFO/revenue guide points running at or slightly below where consensus had drifted, there's no strong upside catalyst for estimate upgrades, but resilient occupancy/low supply also limits downside cuts. Because the stock is trading almost exactly at the implied EQR swap-ratio value, day-to-day price action over the next week should mostly track the merger arb spread and EQR's own price rather than extend or reverse on the print itself — i.e., stabilize near the initial reaction rather than follow through or fade sharply. |
LOW |